Patients with metastatic renal cell carcinoma treated with
cabozantinib in the Czech Republic: analysis of four cancer
centers

J 2022

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

RICHTER, Igor, Alexandr POPRACH, Anezka ZEMANKOVA, Tomas BUCHLER, Jiri BARTOS et. al.

Základní údaje

Originální název

Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers

Autoři

RICHTER, Igor (203 Česká republika, garant), Alexandr POPRACH (203 Česká republika, domácí), Anezka ZEMANKOVA (203 Česká republika), Tomas BUCHLER (203 Česká republika), Jiri BARTOS (203 Česká republika), Vladimir SAMAL (203 Česká republika), Hana STUDENTOVA (203 Česká republika), Aneta ROZSYPALOVA (203 Česká republika), Josef DVORAK (203 Česká republika), Ondrej BROM (203 Česká republika) a Bohuslav MELICHAR (203 Česká republika)

Vydání

Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2022, 1213-8118

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 0.900

Kód RIV

RIV/00216224:14110/22:00128267

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.5507/bp.2020.055

UT WoS

000731338900001

Klíčová slova anglicky

cabozantinib; metastases; renal cell carcinoma; toxicity

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 11:07, Mgr. Tereza Miškechová

Anotace

V originále

Aim. The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and Methods. Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. Results. 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. Conclusion. The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients

Citovat

RICHTER, Igor, Alexandr POPRACH, Anezka ZEMANKOVA, Tomas BUCHLER, Jiri BARTOS, Vladimir SAMAL, Hana STUDENTOVA, Aneta ROZSYPALOVA, Josef DVORAK, Ondrej BROM a Bohuslav MELICHAR. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. Biomedical Papers, Olomouc: Palacky University. Olomouc: Palacky University, 2022, roč. 166, č. 1, s. 97-104. ISSN 1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2020.055.

@article{2249589,
   author = {Richter, Igor and Poprach, Alexandr and Zemankova, Anezka and Buchler, Tomas and Bartos, Jiri and Samal, Vladimir and Studentova, Hana and Rozsypalova, Aneta and Dvorak, Josef and Brom, Ondrej and Melichar, Bohuslav},
   article_location = {Olomouc},
   article_number = {1},
   doi = {http://dx.doi.org/10.5507/bp.2020.055},
   keywords = {cabozantinib; metastases; renal cell carcinoma; toxicity},
   language = {eng},
   issn = {1213-8118},
   journal = {Biomedical Papers, Olomouc: Palacky University},
   title = {Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers},
   url = {https://biomed.papers.upol.cz/artkey/bio-202201-0014_patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-in-the-czech-republic-analysis-of-four.php},
   volume = {166},
   year = {2022}
}

TY  - JOUR
ID  - 2249589
AU  - Richter, Igor - Poprach, Alexandr - Zemankova, Anezka - Buchler, Tomas - Bartos, Jiri - Samal, Vladimir - Studentova, Hana - Rozsypalova, Aneta - Dvorak, Josef - Brom, Ondrej - Melichar, Bohuslav
PY  - 2022
TI  - Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers
JF  - Biomedical Papers, Olomouc: Palacky University
VL  - 166
IS  - 1
SP  - 97-104
EP  - 97-104
PB  - Palacky University
SN  - 12138118
KW  - cabozantinib
KW  - metastases
KW  - renal cell carcinoma
KW  - toxicity
UR  - https://biomed.papers.upol.cz/artkey/bio-202201-0014_patients-with-metastatic-renal-cell-carcinoma-treated-with-cabozantinib-in-the-czech-republic-analysis-of-four.php
N2  - Aim. The aim of this study was to retrospectively analyze treatment outcomes and tolerance in patients in whom cabozantinib was used after previous targeted therapy. Patients and Methods. Cabozantinib was administered in dose 60 mg/day, a subset of patients received initial dose of 40 mg/day. The treatment was administered until to progression or unacceptable toxicity. CT scans were assessed according to the RECIST 1.1 and toxicity of treatment was assessed based on the CTCAE (version 4). Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. All statistics were evaluated at the significance level alpha = 0.05. Results. 54 patients with metastatic renal cell carcinoma (mRCC) were evaluated. Median PFS in all patients treated with cabozantinib was 9.3 months (95% CI 5.3 - 13.3). One-year survival was 85.2% (95% CI 72.9 - 93.4%). Treatment response was observed in 45.9% of cases, including one complete remission. Cox regression analysis demonstrated that presence of subsequent treatment was the only factor with a significant effect on OS (P=0.008). Adverse events occurred in 88.9% of patients, grade 3 - 4 in 46.3%. Conclusion. The analysis of our cohort of patients treated with cabozantinib in the second or higher lines of treatment showed that cabozantinib represents an effective and safe therapy and contributes to longer survival of our mRCC patients
ER  -

RICHTER, Igor, Alexandr POPRACH, Anezka ZEMANKOVA, Tomas BUCHLER, Jiri BARTOS, Vladimir SAMAL, Hana STUDENTOVA, Aneta ROZSYPALOVA, Josef DVORAK, Ondrej BROM a Bohuslav MELICHAR. Patients with metastatic renal cell carcinoma treated with cabozantinib in the Czech Republic: analysis of four cancer centers. \textit{Biomedical Papers, Olomouc: Palacky University}. Olomouc: Palacky University, 2022, roč.~166, č.~1, s.~97-104. ISSN~1213-8118. Dostupné z: https://dx.doi.org/10.5507/bp.2020.055.

Podrobný výpis o publikaci